You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Bharat Biotech told to submit complete phase 2 data of its Covid-19 vaccine

Bharat Biotech, which had sought DCGI's nod for conducting phase-3 clinical trials of its Covid-19 vaccine candidate, has been asked to submit complete data of the ongoing phase-2 trial

Topics
Bharat Biotech | Coronavirus Vaccine | Coronavirus

Press Trust of India  |  New Delhi 

Coronavirus, vaccine, covid
File Photo

Bharat Biotech, which had sought DCGI's nod for conducting phase-3 clinical trials of its COVID-19 vaccine candidate, has been asked to submit complete safety and immunogenicity data of the ongoing phase-2 trial, besides providing some clarifications, before proceeding for the next stage.

The vaccine candidate -- 'Covaxin' -- is being indigenously developed by the in collaboration with the Indian Council of Medical Research (ICMR).

According to officials, the Hyderabad-based vaccine maker applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission to conduct phase-3 randomised double-blind placebo-controlled multicentre trial of its COVID-19 vaccine candidate.

The firm in its application said that the study would cover 28,500 subjects aged 18 years and above and would be conducted in 19 sites -- including Delhi, Mumbai, Patna and Lucknow -- across 10 states.

According to sources, the phase-2 trial of the Covaxin is going on and the second dose is yet to be given to volunteers at some sites.

"The company presented phase-3 clinical trial protocol along with interim data of phase 1 and 2 clinical trials," an official said.

The subject expert committee (SEC) at the Central Drugs Standard Control Organisation(CDSCO) deliberated on the application on October 5.

"After a detailed deliberation, the committee opined that the design of the phase-3 study is in principle satisfactory except for clarification on definition of asymptomatic, etc.

"However, the study should be initiated with appropriate dose identified from the phase-2 safety and immunogenicity data. Accordingly, the firm should submit safety and immunogenicity data from phase-2 trial for consideration," the panel said in its recommendations.

The SEC during its discussion also observed that the vaccine was well-tolerated in all dose groups and no serious adverse events have been reported so far, a source said.

The most common adverse event was pain at the injection site, which resolved transiently, the source said.

The phase-3 clinical trial application proposed a dose of 0.5 ml on day 0 and 28, sources said.

Besides, Bharat Biotech, indigenously developed vaccine candidate by Zydus Cadila Ltd is in the phase 2 of the human clinical trials.

The Pune-based Serum Institute of India, which has partnered with AstraZeneca for manufacturing the Oxford COVID-19 vaccine candidate, is also conducting Phase 2 and 3 human clinical trials of the candidate in India.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, October 10 2020. 15:33 IST
RECOMMENDED FOR YOU